Suven Life Sciences Limited (SUVEN) - Total Assets
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) holds total assets worth Rs3.37 Billion INR (≈ $36.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Suven Life Sciences Limited cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Suven Life Sciences Limited - Total Assets Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's total assets have evolved over time, based on quarterly financial data. Explore SUVEN long-term investment intensity to see how much of total assets are deployed in long-term investments.
Suven Life Sciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Suven Life Sciences Limited's total assets of Rs3.37 Billion consist of 55.8% current assets and 44.2% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs227.01 Million | 27.9% |
| Accounts Receivable | Rs14.12 Million | 1.0% |
| Inventory | Rs2.38 Million | 0.2% |
| Property, Plant & Equipment | Rs594.82 Million | 44.0% |
| Intangible Assets | Rs1.81 Million | 0.1% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SUVEN company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suven Life Sciences Limited's current assets represent 55.8% of total assets in 2025, an increase from 37.7% in 2005.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2025, up from 1.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 44.0% of total assets.
Suven Life Sciences Limited Competitors by Total Assets
Key competitors of Suven Life Sciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Suven Life Sciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.11 | 10.40 | 3.64 |
| Quick Ratio | 5.11 | 10.36 | 3.63 |
| Cash Ratio | 0.02 | 4.74 | 0.00 |
| Working Capital | Rs2.24 Billion | Rs1.69 Billion | Rs452.96 Million |
Suven Life Sciences Limited - Advanced Valuation Insights
This section examines the relationship between Suven Life Sciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.66 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | -52.6% |
| Total Assets | Rs1.35 Billion |
| Market Capitalization | $740.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Suven Life Sciences Limited's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Suven Life Sciences Limited's assets decreased by 52.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Suven Life Sciences Limited (2005–2025)
The table below shows the annual total assets of Suven Life Sciences Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.35 Billion ≈ $14.62 Million |
-52.55% |
| 2024-03-31 | Rs2.85 Billion ≈ $30.81 Million |
-26.74% |
| 2023-03-31 | Rs3.89 Billion ≈ $42.06 Million |
+259.99% |
| 2022-03-31 | Rs1.08 Billion ≈ $11.68 Million |
-15.87% |
| 2021-03-31 | Rs1.28 Billion ≈ $13.89 Million |
-29.41% |
| 2020-03-31 | Rs1.82 Billion ≈ $19.68 Million |
-82.49% |
| 2019-03-31 | Rs10.39 Billion ≈ $112.35 Million |
+13.72% |
| 2018-03-31 | Rs9.14 Billion ≈ $98.79 Million |
+11.99% |
| 2017-03-31 | Rs8.16 Billion ≈ $88.22 Million |
+3.83% |
| 2016-03-31 | Rs7.86 Billion ≈ $84.96 Million |
+1.62% |
| 2015-03-31 | Rs7.73 Billion ≈ $83.61 Million |
+58.88% |
| 2014-03-31 | Rs4.87 Billion ≈ $52.63 Million |
+45.64% |
| 2013-03-31 | Rs3.34 Billion ≈ $36.13 Million |
+17.24% |
| 2012-03-31 | Rs2.85 Billion ≈ $30.82 Million |
+27.43% |
| 2011-03-31 | Rs2.24 Billion ≈ $24.19 Million |
+9.22% |
| 2010-03-31 | Rs2.05 Billion ≈ $22.14 Million |
+10.00% |
| 2009-03-31 | Rs1.86 Billion ≈ $20.13 Million |
-6.24% |
| 2008-03-31 | Rs1.99 Billion ≈ $21.47 Million |
+14.60% |
| 2007-03-31 | Rs1.73 Billion ≈ $18.74 Million |
+21.13% |
| 2006-03-31 | Rs1.43 Billion ≈ $15.47 Million |
+5.34% |
| 2005-03-31 | Rs1.36 Billion ≈ $14.68 Million |
-- |
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more